Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 307

1.

Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database.

Papamichael D, Renfro LA, Matthaiou C, Yothers G, Saltz L, Guthrie KA, Van Cutsem E, Schmoll HJ, Labianca R, André T, O'Connell M, Alberts SR, Haller DG, Kountourakis P, Sargent DJ; Adjuvant Colon Cancer Endpoints (ACCENT) Group.

J Geriatr Oncol. 2016 Jul 25. pii: S1879-4068(16)30088-1. doi: 10.1016/j.jgo.2016.07.002. [Epub ahead of print]

PMID:
27468630
2.

Beyond Composite Endpoints Analysis: Semicompeting Risks as an Underutilized Framework for Cancer Research.

Jazić I, Schrag D, Sargent DJ, Haneuse S.

J Natl Cancer Inst. 2016 Jul 5;108(12). pii: djw154. doi: 10.1093/jnci/djw154. Print 2016 Dec.

PMID:
27381741
3.

Adjuvant Therapy for Colon Cancer: Small Steps Toward Precision Medicine.

Grothey A, Sargent DJ.

JAMA Oncol. 2016 Jun 6. doi: 10.1001/jamaoncol.2016.2304. [Epub ahead of print] No abstract available.

PMID:
27273467
4.

Genotyping-by-sequencing in an orphan plant species Physocarpus opulifolius helps identify the evolutionary origins of the genus Prunus.

Buti M, Sargent DJ, Mhelembe KG, Delfino P, Tobutt KR, Velasco R.

BMC Res Notes. 2016 May 11;9(1):268. doi: 10.1186/s13104-016-2069-4.

5.

Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147.

Phipps AI, Shi Q, Limburg PJ, Nelson GD, Sargent DJ, Sinicrope FA, Chan E, Gill S, Goldberg RM, Kahlenberg M, Nair S, Shields AF, Newcomb PA, Alberts SR; Alliance for Clinical Trials in Oncology.

Int J Cancer. 2016 Sep 1;139(5):986-95. doi: 10.1002/ijc.30135. Epub 2016 May 9.

PMID:
27060850
6.

Flexible Bayesian survival modeling with semiparametric time-dependent and shape-restricted covariate effects.

Murray TA, Hobbs BP, Sargent DJ, Carlin BP.

Bayesian Anal. 2016 Jun;11(2):381-402. Epub 2015 May 14.

PMID:
27042243
7.

New insights into the evaluation of randomized controlled trials for rare diseases over a long-term research horizon: a simulation study.

Bayar MA, Le Teuff G, Michiels S, Sargent DJ, Le Deley MC.

Stat Med. 2016 Aug 30;35(19):3245-58. doi: 10.1002/sim.6942. Epub 2016 Mar 30.

PMID:
27027783
8.

Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database.

Cheung WY, Renfro LA, Kerr D, de Gramont A, Saltz LB, Grothey A, Alberts SR, Andre T, Guthrie KA, Labianca R, Francini G, Seitz JF, O'Callaghan C, Twelves C, Van Cutsem E, Haller DG, Yothers G, Sargent DJ.

J Clin Oncol. 2016 Apr 10;34(11):1182-9. doi: 10.1200/JCO.2015.65.1158. Epub 2016 Feb 8.

PMID:
26858337
9.

One good DNA-damage deserves another: Oxaliplatin in MSI-high colon cancer.

Hochster HS, Sargent DJ.

J Natl Cancer Inst. 2016 Feb 5;108(7). pii: djw011. doi: 10.1093/jnci/djw011. Print 2016 Jul. No abstract available.

PMID:
26851803
10.

Clinical trial designs incorporating predictive biomarkers.

Renfro LA, Mallick H, An MW, Sargent DJ, Mandrekar SJ.

Cancer Treat Rev. 2016 Feb;43:74-82. doi: 10.1016/j.ctrv.2015.12.008. Epub 2016 Jan 5. Review.

PMID:
26827695
11.

Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database.

Shah MA, Renfro LA, Allegra CJ, André T, de Gramont A, Schmoll HJ, Haller DG, Alberts SR, Yothers G, Sargent DJ.

J Clin Oncol. 2016 Mar 10;34(8):843-53. doi: 10.1200/JCO.2015.63.0558. Epub 2016 Jan 25.

PMID:
26811529
12.

American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine.

Kattan MW, Hess KR, Amin MB, Lu Y, Moons KG, Gershenwald JE, Gimotty PA, Guinney JH, Halabi S, Lazar AJ, Mahar AL, Patel T, Sargent DJ, Weiser MR, Compton C; members of the AJCC Precision Medicine Core.

CA Cancer J Clin. 2016 Jan 19. doi: 10.3322/caac.21339. [Epub ahead of print]

13.

Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance).

Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Grothey A, Polite B, Chan E, Gill S, Kahlenberg MS, Nair SG, Shields AF, Goldberg RM, Diasio RB.

Pharmacogenet Genomics. 2016 Mar;26(3):133-7. doi: 10.1097/FPC.0000000000000197.

PMID:
26658227
14.

HaploSNP affinities and linkage map positions illuminate subgenome composition in the octoploid, cultivated strawberry (Fragaria×ananassa).

Sargent DJ, Yang Y, Šurbanovski N, Bianco L, Buti M, Velasco R, Giongo L, Davis TM.

Plant Sci. 2016 Jan;242:140-50. doi: 10.1016/j.plantsci.2015.07.004. Epub 2015 Jul 10.

PMID:
26566832
15.

Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients.

Liu H, Tan AD, Qin R, Sargent DJ, Grothey A, Buckner JC, Schaefer PL, Sloan JA.

SOJ Anesthesiol Pain Manag. 2015;2(2). doi: 10.15226/2374-684X/2/2/00120. Epub 2015 Apr 10.

16.

Mapping QTL associated with Verticillium dahliae resistance in the cultivated strawberry (Fragaria × ananassa).

Antanaviciute L, Šurbanovski N, Harrison N, McLeary KJ, Simpson DW, Wilson F, Sargent DJ, Harrison RJ.

Hortic Res. 2015 Mar 11;2:15009. doi: 10.1038/hortres.2015.9. eCollection 2015.

17.

Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.

Renfro LA, Loupakis F, Adams RA, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Falcone A, Tebbutt NC, Punt CJ, Hecht JR, Bokemeyer C, Van Cutsem E, Goldberg RM, Saltz LB, de Gramont A, Sargent DJ, Lenz HJ.

J Clin Oncol. 2016 Jan 10;34(2):144-50. doi: 10.1200/JCO.2015.61.6441. Epub 2015 Oct 26.

PMID:
26503203
18.

Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods.

An MW, Han Y, Meyers JP, Bogaerts J, Sargent DJ, Mandrekar SJ.

J Clin Oncol. 2015 Dec 1;33(34):4048-57. doi: 10.1200/JCO.2015.60.8778. Epub 2015 Oct 26.

PMID:
26503199
19.

Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes: The ACOSOG Z6051 Randomized Clinical Trial.

Fleshman J, Branda M, Sargent DJ, Boller AM, George V, Abbas M, Peters WR Jr, Maun D, Chang G, Herline A, Fichera A, Mutch M, Wexner S, Whiteford M, Marks J, Birnbaum E, Margolin D, Larson D, Marcello P, Posner M, Read T, Monson J, Wren SM, Pisters PW, Nelson H.

JAMA. 2015 Oct 6;314(13):1346-55. doi: 10.1001/jama.2015.10529.

PMID:
26441179
20.

Introduction to special issue on biomarker-based clinical trial designs in oncology.

Sargent DJ, Mandrekar S, Grothey A.

Chin Clin Oncol. 2015 Sep;4(3):28. doi: 10.3978/j.issn.2304-3865.2015.09.05. No abstract available.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk